2020-2027 Analysis and Review Cisatracurium Besylate Market
Cisatracurium Besylate Market By Application (Mechanical Ventilation, Skeletal Muscle Relaxant, and Others), By End User (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027
The cisatracurium besylate market was valued at USD458.4 Mn by 2019. Rising prevalence of pulmonary disorders and an increasing number of abdominal surgeries performed together to drive the cisatracurium besylate market growth. Furthermore the effective implementation of guidelines pertaining to anesthesia medicines the frequency of cisatracurium besylate as an anesthesia adjuvant has increased to a larger extent.
Cisatracurium besylate is a non-depolarizing skeletal muscle relaxant that is administered intravenously. It has an intermediate onset of action and duration of action likewise, it binds competitively with the cholinergic receptors on the motor plate end which eventually results in antagonizing the action of acetylcholine resulting in the blockade of neuromuscular transmission. It is an isomer of atracurium besylate with 3 folds potency in comparison to atracurium besylate. It degrades at physiological pH and temperature by organ independent Hoffman elimination by forming the compound called laudanosine which gets further metabolized and finally excreted via urine.
The major segments related to the cisatracurium besylate market are:
By Application (2017–2027; US$ Mn)
Mechanical Ventilation
Skeletal Muscle Relaxant
Others
By End User (2017–2027; US$ Mn)
Hospital Pharmacy
Retail Pharmacy
Others
Geography Segment(2017–2027; US$ Mn)
North America
United States
Canada
Europe
United Kingdom
Germany
Rest of Europe
Asia Pacific
China
Japan
Rest of Asia Pacific
Latin America (LATAM)
Brazil
Mexico
Rest of Latin America
Middle East and Africa (MEA)
GCC
Rest of MEA
Justification for study?
Report gist?
Significant customers?
Segment Analysis
Skeletal muscle relaxants are dominating the application segment for the cisatracurium besylate market. They are frequently employed for relaxing the muscles in the abdomen or chest region for surgeries to be performed in those regions. They are also employed for relaxing eye muscles in eye surgeries and permits easy movements of joints and bones during the joint surgery. Mechanical ventilation is anticipated to register faster growth in the near future on account of the rising prevalence of pulmonary disorders with breathing problems.
Hospital pharmacy is reigning the end-user segment for the cisatracurium besylate market. The positive attributes which determine its impressive market growth are immaculate drug dosage monitoring and precise compounding of skeletal muscle relaxant employed in surgical procedures in the intensive care units in the hospitals. Retail pharmacy is constantly growing in the developing nations on account of the presence of a huge generic drug market and the capability to provide medicines at affordable prices.
North America is holding the largest market share in the geography segment for the cisatracurium besylate market. The factors that determine its market dominance are a significant rise in the number of patients admitted in the intensive care units (ICU) receiving tracheal intubation in the treatment of pulmonary disorders. Furthermore the effective implementation of guidelines pertaining to anesthesia has included the popularity of using cisatracurium besylate as an anesthesia adjunct to facilitate mechanical ventilation. Domicile of major players such as AbbVie, Inc., GlaxoSmithKline, Plc., Sandoz, Inc., etc., further accelerates the market growth in the region. In Europe the market growth is driven by contributing factors such as affordable reimbursement scenario for the use of cisatracurium besylate in surgical procedures and proactive role adopted by the European Medical Agency (EMA) for the adoption of cisatracurium besylate as a skeletal muscle relaxant. Asia Pacific is set to register sturdy market growth owing to the rising prevalence of acute respiratory distress syndrome and trauma requiring mechanical ventilation to facilitate breathing and constant rise in the medical tourism industry.
$4,600 | |
$6,600 | |
$9,500 |
Request customization |
Get market alerts |
Ask for regional data |
Ask for country-specific data |